Topical Agents for Premature Ejaculation: A Review
| Autor: | Kristin Christiansen, Tricia Zubert, Paul Pawlicki, Stacey Seibel, Alejandro Carranza, Michael J. Butcher |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Urology Endocrinology Diabetes and Metabolism 030232 urology & nephrology Psychological intervention Relative cost Condoms 03 medical and health sciences 0302 clinical medicine Endocrinology Pharmacotherapy Premature ejaculation medicine Humans Anesthetics Local Premature Ejaculation Intensive care medicine 030219 obstetrics & reproductive medicine business.industry Obstetrics and Gynecology Treatment options Ejaculatory latency Clinical trial Psychiatry and Mental health Reproductive Medicine Topical agents medicine.symptom Diterpenes business |
| Zdroj: | Sexual medicine reviews. 8(1) |
| ISSN: | 2050-0521 |
| Popis: | Introduction Premature ejaculation (PE) is among the most common sexual dysfunctions that affect men. Currently, topical medications are considered a first-line treatment option for PE, with no specific medication having market approval in the United States specifically for the treatment of PE. Topical agents for PE include eutectic mixture of local anesthetics cream, topical eutectic mixture for premature ejaculation spray, severance secret-cream, resiniferatoxin, and an assortment of over-the-counter treatments, including medicated condoms, sprays, and wipes. Aim Given the paucity of controlled studies for these treatment modalities, the goal of this article is to review the currently available options for PE to help educate providers in appropriate treatment options. Methods Comprehensive review of published literature, as well as clinical experience were evaluated to determine efficacy of known treatments for PE. Main Outcome Measure The topical treatment options and efficacy of these options for PE were reviewed. Eutectic mixture of local anesthetics, topical eutectic mixture for premature ejaculation, severance secret-cream, resiniferatoxin, and medicated condoms are the mainstay of treatment. Each has certain risks and benefits associated with use as described, as well as relative cost of use. Results Although data supporting the effectiveness of topical agents for PE is limited, prior clinical trials demonstrate increases in timed intravaginal ejaculatory latency time and improved patient-partner sexual satisfaction survey scores on some treatment options. Conclusion More research is needed to evaluate efficacy, cost-effectiveness, potential side effects, and benefits of combined medical and psychological intervention for better ejaculatory control. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|